Navigation Links
HybridSPE(TM)-Precipitation Technology Wins 2009 Scientists' Choice Award for Best New Separations Product in 2008

HybridSPE-Precipitation (HybridSPE-PPT) technology combines the simplicity of protein precipitation with the selectivity of SPE for the targeted removal of phospholipids and proteins from biological samples prior to LC-MS/MS analysis

ST. LOUIS, April 8 /PRNewswire-FirstCall/ -- Supelco, a division of Sigma-Aldrich (Nasdaq: SIAL), and a leading supplier of chromatography products for analysis and purification, announces that its HybridSPE-Precipitation technology ( has won the 2009 Scientists' Choice Award for Best New Separations Product in 2008. is one of the leading online resources for applied chemists, clinical chemists and life scientists. The Scientists' Choice Award was based on an independent poll of over 25,000 scientists within the community. The award was announced at Pittconn(R) 2009 held recently in Chicago, IL.

"The advent of LC-MS technology has resulted in a wealth of benefits in terms of analysis speed and sensitivity, but sample prep still was a bottleneck within the overall bioanalytical process," said An Trinh, Product Manager of Sample Prep at Supelco. "Our goal was to deliver a new and innovative sample prep platform that would be simple enough in use to employ in a high throughput setting while simultaneously improving the overall quality of the researchers' data. We are very happy to learn that our efforts have been recognized by the scientific community."

HybridSPE-Precipitation (HybridSPE-PPT) technology is a simple and generic sample preparation platform designed for the gross level removal of endogenous protein and phospholipid interferences from biological plasma and serum prior to LC-MS or LC-MS/MS analysis.

In pharmaceutical bioanalysis, researchers develop and run various assays to quantitate drugs, pharmaceutical candidates, and metabolites in biological fluids such as serum and plasma. Excessive background from endogenous matrix components has always been a great concern in quantitative bioanalysis, and has become paramount with decreasing analytical run times. In bioanalytical mass spectrometry, the issue of excessive background contributes to the growing problem of ion-suppression.

One of the major causes of ion-suppression in bioanalysis is the presence of phospholipids during LC-MS or LC-MS-MS analysis in the positive ion electrospray mode (+ESI). Phospholipids are the second largest lipid component in biological matrices after triglycerides, and are typically present in extremely high concentrations in biological plasma samples.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at

Sigma-Aldrich and Supelco are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Novel Technology Breaks Through Cancer Pain
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Advanced Cell Technology Announces Proposed Financing
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. China Technology Announces New Chief Financial Officer
11. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
Post Your Comments:
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):